Jurata Inc.
Jurata Thin Film is focused on transforming the formulation, stability, distribution, and administration of biologics, vaccines, and advanced therapeutics. The company develops thermostable formulations that eliminate or reduce cold chain requirements, enabling needle-free, flexible administration, improved access globally, and greater manufacturing efficiency across a broad range of biologics and therapeutic modalities.
Industries
N/A
Nr. of Employees
small (1-50)
Jurata Inc.
870 Martin Luther King Jr. Boulevard, Chapel Hill, North Carolina 27514
Products
Thermostable drug formulations in thin film, liquid, or vial forms enabling room temperature stability and flexible administration, including sublingual, oral, injectable, and intranasal routes.
Thermostable drug formulations in thin film, liquid, or vial forms enabling room temperature stability and flexible administration, including sublingual, oral, injectable, and intranasal routes.
Services
Design and creation of customized thermostable formulations for biologics, vaccines, and gene therapies, tailored for stability and multiple administration routes.
Works with partners to adapt the technology for specific stability, storage, and delivery needs, enabling integration into existing or novel drug development programs.
Design and creation of customized thermostable formulations for biologics, vaccines, and gene therapies, tailored for stability and multiple administration routes.
Works with partners to adapt the technology for specific stability, storage, and delivery needs, enabling integration into existing or novel drug development programs.
Expertise Areas
- Thermostable formulation of biologics and vaccines
- Drug delivery platform development
- Biologics manufacturing optimization
- Needle-free and alternative administration routes
Key Technologies
- Thin film drug delivery
- Lipid nanoparticle stabilization
- Sublingual and buccal drug delivery
- Thermostable formulation technology
Key People
Tim Obara
Chief Executive Officer
Irnela Bajrovic, PhD
Scientific Co-Founder, Interim CSO
Tim Ferguson
General Counsel
Sheila Ann Mikhail, JD, MBA
Co-Founder, Executive Chair
R. Jude Samulski, PhD
Co-Founder, Board Member
Tim Obara
Chief Executive Officer
Irnela Bajrovic, PhD
Scientific Co-Founder, Interim CSO
Tim Ferguson
General Counsel
Sheila Ann Mikhail, JD, MBA
Co-Founder, Executive Chair
R. Jude Samulski, PhD
Co-Founder, Board Member
News & Updates
Selected as a company for the Blue Knight program for work on innovative thin film formulations enabling vaccine stability at room temperature and needle-free administration.
Received partnership and funding from CEPI to advance thermostable, needle-free mRNA vaccine films for global deployment.
Awarded $1M funding for joint development of shelf-stable, needle-free COVID-19 booster vaccine with CastleVax.
CEPI partnered with Jurata to support development of thermostable, needle-free mRNA vaccine films aimed at improving global access, especially in underserved regions.
Jurata, in partnership with CastleVax, was awarded $1 million to further the development of a thermostabilized, needle-free COVID-19 vaccine.
Jurata was selected to join Blue Knight, based on its thin film formulation for room-temperature-stabilized, needle-free vaccines.
Selected as a company for the Blue Knight program for work on innovative thin film formulations enabling vaccine stability at room temperature and needle-free administration.
Received partnership and funding from CEPI to advance thermostable, needle-free mRNA vaccine films for global deployment.
Awarded $1M funding for joint development of shelf-stable, needle-free COVID-19 booster vaccine with CastleVax.
CEPI partnered with Jurata to support development of thermostable, needle-free mRNA vaccine films aimed at improving global access, especially in underserved regions.
Jurata, in partnership with CastleVax, was awarded $1 million to further the development of a thermostabilized, needle-free COVID-19 vaccine.
Jurata was selected to join Blue Knight, based on its thin film formulation for room-temperature-stabilized, needle-free vaccines.